LUNG News & Events

The company said, "Pulmonx expects revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company expects gross margin for the full year 2026 to be approximately75%. Pulmonx expects total operating expenses for the full year 2026 to fall within the range of $113 million to $115 million, inclusive of approximately $21 million of non-cash stock-based compensation. The Company expects cash, cash equivalents, and marketable securities to decrease by approximately $23 million for the full year 2026 assuming no additional drawdowns under the Company's recently closed credit facility."

Reports Q4 revenue $22.6M, consensus $21.73M. "While our recent performance reflects a period of transition, we see a substantial opportunity to rebuild momentum through a clear operating plan focused on our highest-impact initiatives, including reaccelerating commercial growth and advancing our clinical pipeline," said Glen French, President and Chief Executive Officer of Pulmonx. "We have strengthened our balance sheet and are executing with increased focus and financial discipline to align investments with growth expectations to support a sustainable path to profitability."

Consensus $90.69M. The company said, "Pulmonx is updating its 2025 financial outlook and expects full year 2025 total revenue to be in the range of $89 million to $90 million. The Company expects gross margin for the full year 2025 to be approximately 73%. Pulmonx expects total operating expenses for the full year 2025 to fall within the range of $125 million to $126 million, inclusive of approximately $21 million of non-cash stock-based compensation. The Company's updated guidance does not anticipate any potential impact from future tariffs or trade policy changes, or their effects on the global macroeconomic environment, including foreign currency fluctuations."